Every article, report, and earnings note where TEM appears.
Tempus AI is scaling quickly across diagnostics and data licensing, with Q2 revenue up 22% and management lifting 2026 guidance. The stock still looks like a Hold as execution and cash generation need to catch up with a premium valuation.
Tempus AI, Inc. (TEM) rises after a new Recursion Pharmaceuticals partnership extension and RNA model agreement fueled renewed interest in its healthcare AI platform. Strong volume, recent FDA clearance, and ARPA-H funding added to the rally, though the stock now trades above several analyst targets.
Tempus AI, Inc. (TEM) climbs after a positive Merck-Moderna melanoma result sparked fresh enthusiasm for precision oncology and MRD testing. The rally also follows solid Q2 results and renewed attention on Tempus’ Personalis acquisition, though the stock remains volatile and richly valued.
TEM’s 24.1% headline-free surge looks like investors repricing a real profitability inflection, not chasing an empty AI story. Q2 revenue growth, a guidance raise and a path to positive cash flow give the rally a fundamental anchor despite expensive valuation.
TEM's sharp rally is absorbing Personalis dilution risk because the growth engine is getting harder for the market to ignore. Revenue growth, MRD adoption and repeated earnings beats give the bull case more weight than the deal's near-term optics.
TEM's 13% surge is running ahead of an unprofitable business and a $1.5 billion Personalis deal that adds scale before it adds clean earnings. Strong revenue growth is real, but dilution, cash needs, and insider selling make this rally one to fade rather than chase.
GNQ Insilico is a TechBio and precision-medicine company going public through a merger with IB Acquisition Corp. (Nasdaq: IBAC), with the deal originally expected to close in Q3 2026. The bull case is an AI-driven drug discovery platform; the bear case is a small trust, heavy financing dependence, and meaningful dilution risk.
Tempus AI is getting sold on supposedly bullish news because the market still does not trust growth financed with more paper. The Personalis deal, fresh convert dilution, and persistent losses are colliding with a stock that was never priced for execution mistakes.
This countdown spans AI-native drug discovery, computational chemistry, genomics, diagnostics, antibody platforms and data-rich biotech businesses.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate TEM ReportCancel anytime